MX2010007927A - Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina. - Google Patents

Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.

Info

Publication number
MX2010007927A
MX2010007927A MX2010007927A MX2010007927A MX2010007927A MX 2010007927 A MX2010007927 A MX 2010007927A MX 2010007927 A MX2010007927 A MX 2010007927A MX 2010007927 A MX2010007927 A MX 2010007927A MX 2010007927 A MX2010007927 A MX 2010007927A
Authority
MX
Mexico
Prior art keywords
pyrrolo
pyrimidine
pyridine
amine derivatives
cell
Prior art date
Application number
MX2010007927A
Other languages
English (en)
Inventor
Dieter Dorsch
Christian Sirrenberg
Thomas J J Mueller
Eugen Merkul
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010007927A publication Critical patent/MX2010007927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la fórmula I (ver fórmula (I)) en donde R1, R2, R3, R4 Y R5 tienen los significados indicados en la reivindicación 1, son inhibidores de la proliferación celular / vitalidad celular y se pueden emplear para el tratamiento de tumores.
MX2010007927A 2008-01-22 2008-12-23 Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina. MX2010007927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008005493A DE102008005493A1 (de) 2008-01-22 2008-01-22 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
PCT/EP2008/011098 WO2009092431A1 (de) 2008-01-22 2008-12-23 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidin-2-amin-derivative

Publications (1)

Publication Number Publication Date
MX2010007927A true MX2010007927A (es) 2010-08-09

Family

ID=40386204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007927A MX2010007927A (es) 2008-01-22 2008-12-23 Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.

Country Status (14)

Country Link
US (1) US20100292262A1 (es)
EP (1) EP2231664A1 (es)
JP (1) JP5524864B2 (es)
KR (1) KR20100112626A (es)
CN (1) CN101918404A (es)
AR (1) AR070212A1 (es)
AU (1) AU2008348816B2 (es)
BR (1) BRPI0821936A2 (es)
CA (1) CA2712612A1 (es)
DE (1) DE102008005493A1 (es)
IL (1) IL206905A0 (es)
MX (1) MX2010007927A (es)
WO (1) WO2009092431A1 (es)
ZA (1) ZA201005959B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2714688B1 (en) 2011-05-26 2016-02-24 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
US9981962B2 (en) 2014-10-23 2018-05-29 Janssen Pharmaceutica Nv Pyrazole derivatives as NIK inhibitors
JP6603713B2 (ja) 2014-10-23 2019-11-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体
WO2016062790A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
BR112017008045A2 (pt) * 2014-10-23 2017-12-19 Janssen Pharmaceutica Nv compostos como inibidores de nik
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US20080153869A1 (en) * 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SG151327A1 (en) * 2005-09-30 2009-04-30 Vertex Pharmaceuticals Incopor Deazapurines useful as inhibitors of janus kinases
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
BRPI0821936A2 (pt) 2015-06-16
AU2008348816B2 (en) 2011-10-20
DE102008005493A8 (de) 2010-03-25
JP5524864B2 (ja) 2014-06-18
US20100292262A1 (en) 2010-11-18
KR20100112626A (ko) 2010-10-19
CN101918404A (zh) 2010-12-15
DE102008005493A1 (de) 2009-07-23
ZA201005959B (en) 2011-04-28
AR070212A1 (es) 2010-03-25
EP2231664A1 (de) 2010-09-29
AU2008348816A1 (en) 2009-07-30
JP2011510028A (ja) 2011-03-31
WO2009092431A1 (de) 2009-07-30
CA2712612A1 (en) 2009-07-30
IL206905A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2011011488A (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.
UA104731C2 (ru) Ингибиторы р38 мар-киназ
MY159230A (en) P38 map kinase inhibitors
MX2009012708A (es) Derivados de piridazinona.
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
MX2009013077A (es) Derivados dde benzoxazolona.
MY153727A (en) Pyridazinone derivatives
MX2009012709A (es) Derivados de arileter-piridazinona.
EA201200653A1 (ru) Гетариламинохинолины
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
MX2010003368A (es) Derivados de imidazol.
MX2008001538A (es) Aril piridinas y metodos para su uso.
TW200716118A (en) Aminopyrimidines as kinase modulators
TW200718693A (en) Aminopyrimidines as kinase modulators
MX340714B (es) Inhibidores de hsp90.
UA105000C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal